Ndividualized and Combined Effects of Diabetes and Smoking on the Antiplatelet Activity of Ticagrelor in Acute Myocardial Infarction Patients Undergoing Primary PCI
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Platelet Reactivity Index and maximum platelet aggregation
研究概览
简要总结
Background:Diabetes and smoking are common factors found to increase platelet reactivity in patients undergoing primary PCI. Objective: Compare the individualized and combined effects of smoking and diabetes on the antiplatelet activity in patients undergoing primary PCI. Methods: sixty patients were recruited in this study. Patients were allocated to one of four groups according to the diabetes and smoking status. Non smokers- non diabetic patients, smokers non diabetic patients, non smokers diabetic patients, and smokers diabetic patients, 15 patients in each group. All patients received 180 mg ticagrelor before PCI. Platelet reactivity index(PRI) and maximum platelet aggregation were measured 24 hours after ticagrelor loading dose for each patient as indicators for antiplatelet efficacy. PRI and/or MPA values > 50% were defined as high platelet reactivity.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Acute coronary syndrome (ACS) undergoing PCI
排除标准
- •Patients who had a history of severe bleeding, serious bleeding tendency, history of intracranial hemorrhage, signs of active bleeding, thrombocytopenia, uncontrolled hypertension, hypersensitivity to the used drugs (clopidogrel or ticagrelor), concomitant use of strong CYP inducers or inhibitors, and/or severe liver disorders were excluded from the study.
- •Patients with previous history of coronary artery disease, previous PCI or patients administering other antiplatelets were excluded from the current study.
研究组 & 干预措施
Non smokers- non diabetic patients
干预措施: Ticagrelor (Drug)
smokers non diabetic patients
干预措施: Ticagrelor (Drug)
non smokers diabetic patients
干预措施: Ticagrelor (Drug)
smokers diabetic patients
干预措施: Ticagrelor (Drug)
结局指标
主要结局
Platelet Reactivity Index and maximum platelet aggregation
时间窗: 24 hours after PCI
Platelet aggregation indicator
次要结局
未报告次要终点
研究者
Mina Wageh Mohareb
Professor
Cairo University